Cheng Liao

Title: The Innovative Contributions of Cheng Liao

Introduction

Cheng Liao is a prominent inventor based in Jiangsu, China, known for his significant contributions to the field of pharmaceuticals. With a total of four patents to his name, Liao has made strides in developing innovative treatments for tumors and cancers. His work reflects a commitment to advancing medical science and improving patient outcomes.

Latest Patents

Liao's latest patents include groundbreaking research on the use of an anti-PD-1 antibody in combination with famitinib for treating tumors. This innovative approach provides a drug formulation that is both controllable and tolerable in terms of toxicity. Additionally, it effectively reduces adverse reactions associated with the anti-PD-1 antibody, such as reactive capillary endothelial proliferation. Another notable patent involves the development of an anti-OX40 antibody and its antigen-binding fragments, which are utilized in pharmaceutical compositions aimed at treating various cancers.

Career Highlights

Throughout his career, Cheng Liao has worked with esteemed companies such as Jiangsu Hengrui Medicine Company Ltd. and Shanghai Hengrui Pharmaceutical Co., Ltd. His experience in these organizations has allowed him to collaborate on significant projects that push the boundaries of cancer treatment.

Collaborations

Liao has collaborated with notable colleagues, including Lianshan Zhang and Jiahua Jiang, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Cheng Liao's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a key innovator in cancer treatment. His work continues to inspire advancements in medical research and patient care.